About Westchester Capital
Westchester Capital Management (WCM) is a registered investment adviser specializing in liquid alternative investment strategies. We manage a variety of investment portfolios using a combination of strategies to invest in publicly announced event opportunities such as mergers, acquisitions, takeovers, spin-offs and other corporate reorganizations, with the goal of profiting from the timely completion of these transactions.
Our investment management process is designed to deliver consistent results with low correlation to broader market returns, thereby lowering overall portfolio risk and potentially enhancing returns for a diversified portfolio.
Latest News & Commentary from Westchester Capital
Portfolio Managers Roy Behren and Mike Shannon discuss the drivers behind our funds’ Q4 performance and offer their insights on the global markets in our Q4 Quarterly Review for shareholders.
Portfolio Managers Roy Behren and Mike Shannon offer their insights on recent developments in the merger arbitrage environment.
In this Investor’s Business Daily piece, “Why 2018 Could Be an ‘Explosive’ Year For Biotech Mergers,” Westchester Capital Management’s Roy Behren explores Sanofi’s bids for Medivation and Actelion, the heightened activity in the oncology space in terms of immunotherapies and tendency for biotechs to come at significant premiums to trading prices.
The Merger Investor fund (MERFX) has a four-star Morningstar rating out of 114 market-neutral funds, based upon risk-adjusted returns, as of 3/31/18. The overall Morningstar Rating is derived from a weighted average of the funds' 3, 5 and 10-year Morningstar Rating metrics.